

FIGURE S1: A flow chart of project strategy.

Over view of strategy

Screening Phase: Solexa sequencing and TLDA chips profiling on pooled samples (150 Sch v.s. 150 Ctls) Threshold: Solexa: >50copies, >2-fold TLDA: Ct <30, >10-fold Overlapped **Selection Phase:** qRT-PCR in test cohort on individual samples (164 Sch v.s. 187 Ctls) **Threshold:** The Ct value \leq 35, the fold change \geq 2, p value <0.05 **Validation Phase:** qRT-PCR in validation cohort on individual samples (400 Sch v.s. 213Ctls, 162 others) **Threshold:** The Ct value ≤ 35 , the fold change ≥ 2 , p value < 0.05, Follow-up Phase: qRT-PCR on individual samples that finished 1 year follow-up plan (107 samples) **Threshold:** miRNAs show a reversed expression, p value ≤ 0.05 A two-miRNA expression pattern was identified as a specific non-invasive biomarker for schizophrenia diagnosis

FIGURE S2 A–C: The representative standard curve for synthetic single-strand hsa-miR-16, has-miR-130b and has-miR-193a-3p, which were synthesized by Life Technologies, USA). The standard calibration curve was prepared by a 10-fold serial dilution of synthetic miRNAs from 10 fmol/L to 10^7 fmol/L, respectively, and the level of each miRNA was assessed by the qRT-PCR assay. The resulting C_T values were plotted versus the log_{10} of the amount of synthetic hsa-miRNAs. Each point represents the mean of four independent experiments.










FIGURE S3: The distribution of length and components of RNAs in pooled RNA samples. Based on their distribution, miRNAs are main components in total plasma RNA. A represents the control samples and B, the case samples. C shows the components of plasma RNAs in pooled control samples, and D, in pooled case samples.




FIGURE S4: The number of altered miRNAs in schizophrenia plasma captured by Solexa sequencing and TLDA chips




TABLE S1. Detailed information of patients with non-schizophrenia disorders

Disorders	Number of patients
Major depression disorder	84
Anxiety disorder,NOS	23
Mixed anxiety and depressive disorder	12
Mild depressive episode	7
Somatoform disorders	4
Schizophrenic emotional disorders	3
Acute and transient psychiatic disorders, NOS	3
Schizophrenia-like disorders	2
Other non-organic psychotic disorders	2
Other acute and transient psychiatic disorders	2
Depressive episode, NOS	2
Tic disorder	1
Dissociative[Conversive] disorders	1
Generalized anxiety disorder	1
Acute schizophrenic psychiatric disorders	1
Acute stress reaction	1
Acute stress disorder	1
Tension-type stupor state	1
Paranoid personality disorder	1
Other neurosis disorders	1
Alcohol-induced mental and behavioral disorders	1
Bipolar disorders	1
Bipolar disorders, mania at present	1
Sleep Disorder	1
Delusional disorder	1
Undifferentiated somatoform disorder	1
No specific mental disorders	1
Hypochondriac obstacles	1
Depressive episode	1
Total	162

TABLE S2. Recruitment criteria for participants

Inclusion criteria	Exclusion criteria
Patients	
Inform consents signed by patients or guardians	Brain organic diseases or other intercurrent clinical
inform consents signed by patients of guardians	body diseases
	Head trauma history, lost consciousness over
Chinese Han	30min
Diagnosed of schizophrenia by DSM-IV	Diagnosed of other psychosis by DSM-IV
16≤age≤45	Alcohol or other substance dependence or abuse
	Anti-psychiatric drug contraindications involve in
First episode, duration less than 3 years	this study
Without systematic anti-psychiatric treatment,	
continuous regular medication less than 1 month or	Participated in other clinical drug trails in 30 days
continuous irregular medication less than 3 months	
Education≥3 years	Hypophrenia
	Seizures
	Pregnant or breastfeeding women
Controls	
	Accord with the inclusion or exclusion criteria of
Healthy blood donors, male or female	patient group
	Family history of mental or neurological disorders
	Suffered severe head trauma or birth trauma
	Suffered febrile convulsion
	Adopted or single-parent in childhood

TABLE S3. The recovery rates of miR-130b assay under two external standard curves.

	Calibration curves		
Dilution	miR-16	miR-130b	
1	0.38	1.24	
2	0.30	0.89	
4	0.29	0.80	
8	0.28	0.70	
16	0.33	0.80	
32	0.40	0.91	
64	0.51	1.11	
128	0.58	1.17	

The mean±SD was 0.384±0.110 from the miR-16 calibration curve and that was 0.845±0.103 from the miR-miR-130b calibration curve. Pearson correlation analysis shows r=0.384, df=6, p=0.032.

TABLE S4. The recovery rates of miR-193a-3p assay under two external standard curves.

	-		
	Calibration curves		
Dilution	miR-16	miR-193a-3p	
1	0.04	0.96	
2	0.04	0.98	
4	0.03	0.67	
8	0.04	0.81	
16	0.03	0.79	
32	0.04	0.79	
64	0.04	0.87	
128	0.04	0.90	

The mean±SD was 0.034±0.004 from the miR-16 calibration curve and that was 0.953±0.198 from the miR-193a-3p calibration curve. Pearson correlation analysis shows r=0.953, df=6 p=0.0003.